Analyst Ratings For GenMark Diagnostics (NASDAQ:GNMK)
Today, Needham & Company LLC reiterated its Buy rating on GenMark Diagnostics (NASDAQ:GNMK) with a price target of $11.00.
Some recent analyst ratings include
- 1/19/2018-Needham & Company LLC Reiterated Rating of Buy.
- 11/3/2017-Cowen Reiterated Rating of Buy.
- 11/3/2017-Raymond James Financial Reiterated Rating of Outperform .
- 10/30/2017-Canaccord Genuity Reiterated Rating of Buy.
- 9/18/2017-Bank of America initiated coverage with a Buy rating.
- On 12/4/2017 Michael Gleeson, SVP, sold 499 with an average share price of $4.70 per share and the total transaction amounting to $2,345.30.
- On 11/20/2017 Hany Massarany, Insider, sold 8,252 with an average share price of $4.74 per share and the total transaction amounting to $39,114.48.
- On 11/20/2017 Jennifer Anne Williams, SVP, sold 2,719 with an average share price of $4.74 per share and the total transaction amounting to $12,888.06.
- On 11/20/2017 Scott Mendel, CFO, sold 2,879 with an average share price of $4.74 per share and the total transaction amounting to $13,646.46.
- On 11/14/2017 Scott Mendel, CFO, sold 1,777 with an average share price of $4.71 per share and the total transaction amounting to $8,369.67.
- On 11/6/2017 Michael Kagnoff, Director, bought 20,000 with an average share price of $4.13 per share and the total transaction amounting to $82,600.00.
- On 11/2/2017 Eric Stier, SVP, sold 367 with an average share price of $7.24 per share and the total transaction amounting to $2,657.08.
Recent Trading Activity for GenMark Diagnostics (NASDAQ:GNMK)
Shares of GenMark Diagnostics closed the previous trading session at 4.70 down -0.01 0.21% with 4.760000228881836 shares trading hands.